Pliant stock jumps 28% on bexotegrast study update
Source: SeekingAlpha
2025-02-13 10:28:12 ET
More on Pliant Therapeutics
- Pliant Therapeutics: Strange Volatility
- Canaccord Genuity cuts Pliant to hold on study setback
- Pliant stock plunges 61% amid study pause, downgrades
- Seeking Alpha’s Quant Rating on Pliant Therapeutics
- Historical earnings data for Pliant Therapeutics
Read the full article on Seeking Alpha
For further details see:
Pliant stock jumps 28% on bexotegrast study update
Pliant Therapeutics Inc.
NASDAQ: PLRX
PLRX Trading
1.53% G/L:
$1.325 Last:
80,875 Volume:
$1.34 Open:
PLRX Latest News
March 18, 2026 09:00:00 am
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
March 11, 2026 04:05:00 pm
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
PLRX Stock Data
$72,817,521
56,533,434
3.63%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
